Logo image of BLU

BELLUS HEALTH INC (BLU) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:BLU - CA07987C2040 - Common Stock

14.74 USD
0 (0%)
Last: 6/28/2023, 8:00:02 PM
14.74 USD
0 (0%)
After Hours: 6/28/2023, 8:00:02 PM
Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to BLU. BLU was compared to 529 industry peers in the Biotechnology industry. BLU scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. BLU is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

BLU had negative earnings in the past year.
In the past year BLU has reported a negative cash flow from operations.
BLU had negative earnings in each of the past 5 years.
In the past 5 years BLU always reported negative operating cash flow.
BLU Yearly Net Income VS EBIT VS OCF VS FCFBLU Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 0 -20M -40M -60M

1.2 Ratios

The profitability ratios for BLU are negative, so there is not much use analyzing them.
Industry RankSector Rank
ROA N/A
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
BLU Yearly ROA, ROE, ROICBLU Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 0 -10 -20

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for BLU so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
BLU Yearly Profit, Operating, Gross MarginsBLU Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 0 -100K -200K -300K -400K

More info and screens

5

2. Health

2.1 Basic Checks

BLU does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, BLU has more shares outstanding
Compared to 1 year ago, BLU has a worse debt to assets ratio.
BLU Yearly Shares OutstandingBLU Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 20M 40M 60M 80M 100M
BLU Yearly Total Debt VS Total AssetsBLU Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 100M 200M 300M 400M

2.2 Solvency

An Altman-Z score of 103.35 indicates that BLU is not in any danger for bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 103.35, BLU belongs to the top of the industry, outperforming 99.52% of the companies in the same industry.
A Debt/Equity ratio of 0.00 indicates that BLU is not too dependend on debt financing.
Looking at the Debt to Equity ratio, with a value of 0.00, BLU is in line with its industry, outperforming 47.83% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 103.35
ROIC/WACCN/A
WACC7.86%
BLU Yearly LT Debt VS Equity VS FCFBLU Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 0 100M 200M 300M

2.3 Liquidity

BLU has a Current Ratio of 33.42. This indicates that BLU is financially healthy and has no problem in meeting its short term obligations.
BLU has a Current ratio of 33.42. This is amongst the best in the industry. BLU outperforms 97.91% of its industry peers.
A Quick Ratio of 33.42 indicates that BLU has no problem at all paying its short term obligations.
BLU has a better Quick ratio (33.42) than 97.91% of its industry peers.
Industry RankSector Rank
Current Ratio 33.42
Quick Ratio 33.42
BLU Yearly Current Assets VS Current LiabilitesBLU Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 100M 200M 300M

More info and screens

4

3. Growth

3.1 Past

The Earnings Per Share has grown by an nice 12.00% over the past year.
Looking at the last year, BLU shows a decrease in Revenue. The Revenue has decreased by -6.25% in the last year.
BLU shows a very negative growth in Revenue. Measured over the last years, the Revenue has been decreasing by -34.23% yearly.
EPS 1Y (TTM)12%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-53.85%
Revenue 1Y (TTM)-6.25%
Revenue growth 3Y-18.9%
Revenue growth 5Y-34.23%
Sales Q2Q%-25%

3.2 Future

BLU is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 35.40% yearly.
Based on estimates for the next years, BLU will show a very strong growth in Revenue. The Revenue will grow by 654.86% on average per year.
EPS Next Y-27.52%
EPS Next 2Y-17.88%
EPS Next 3Y-9.8%
EPS Next 5Y35.4%
Revenue Next Year-35.9%
Revenue Next 2Y-19.94%
Revenue Next 3Y413.52%
Revenue Next 5Y654.86%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
BLU Yearly Revenue VS EstimatesBLU Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 200M 400M 600M 800M 1B
BLU Yearly EPS VS EstimatesBLU Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 1 2 3

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

BLU reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for BLU. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
BLU Price Earnings VS Forward Price EarningsBLU Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
BLU Per share dataBLU EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 2

4.3 Compensation for Growth

BLU's earnings are expected to decrease with -9.80% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-17.88%
EPS Next 3Y-9.8%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for BLU!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

BELLUS HEALTH INC

NASDAQ:BLU (6/28/2023, 8:00:02 PM)

After market: 14.74 0 (0%)

14.74

0 (0%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-12 2023-05-12/amc
Earnings (Next)08-08 2023-08-08/amc
Inst Owners0%
Inst Owner Change0%
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap1.87B
Revenue(TTM)15.00K
Net Income(TTM)-86.79M
Analysts76
Price Target15.39 (4.41%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)2.73%
Min EPS beat(2)-13.15%
Max EPS beat(2)18.62%
EPS beat(4)1
Avg EPS beat(4)-4.1%
Min EPS beat(4)-20.01%
Max EPS beat(4)18.62%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)7.91%
Min Revenue beat(2)7.91%
Max Revenue beat(2)7.91%
Revenue beat(4)3
Avg Revenue beat(4)30.35%
Min Revenue beat(4)7.91%
Max Revenue beat(4)69.97%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)12.96%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-22.73%
EPS NY rev (1m)0%
EPS NY rev (3m)-30.89%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)-100%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-4.7%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 124601.15
P/FCF N/A
P/OCF N/A
P/B 5.07
P/tB 5.86
EV/EBITDA N/A
EPS(TTM)-0.73
EYN/A
EPS(NY)-0.92
Fwd EYN/A
FCF(TTM)-0.7
FCFYN/A
OCF(TTM)-0.7
OCFYN/A
SpS0
BVpS2.91
TBVpS2.51
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA N/A
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score1
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 33.42
Quick Ratio 33.42
Altman-Z 103.35
F-Score1
WACC7.86%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)12%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-53.85%
EPS Next Y-27.52%
EPS Next 2Y-17.88%
EPS Next 3Y-9.8%
EPS Next 5Y35.4%
Revenue 1Y (TTM)-6.25%
Revenue growth 3Y-18.9%
Revenue growth 5Y-34.23%
Sales Q2Q%-25%
Revenue Next Year-35.9%
Revenue Next 2Y-19.94%
Revenue Next 3Y413.52%
Revenue Next 5Y654.86%
EBIT growth 1Y-24.27%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-150.25%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-150.96%
OCF growth 3YN/A
OCF growth 5YN/A

BELLUS HEALTH INC / BLU FAQ

Can you provide the ChartMill fundamental rating for BELLUS HEALTH INC?

ChartMill assigns a fundamental rating of 4 / 10 to BLU.


Can you provide the valuation status for BELLUS HEALTH INC?

ChartMill assigns a valuation rating of 1 / 10 to BELLUS HEALTH INC (BLU). This can be considered as Overvalued.


Can you provide the profitability details for BELLUS HEALTH INC?

BELLUS HEALTH INC (BLU) has a profitability rating of 0 / 10.


What is the financial health of BELLUS HEALTH INC (BLU) stock?

The financial health rating of BELLUS HEALTH INC (BLU) is 8 / 10.


Can you provide the expected EPS growth for BLU stock?

The Earnings per Share (EPS) of BELLUS HEALTH INC (BLU) is expected to decline by -27.52% in the next year.